Zhou Y, Xu BT, Zhou HY, Shang ZT. Therapeutic insights into epidermal growth factor receptor/reactive oxygen species proto-oncogene 1-receptor co-mutated non-small cell lung cancer: Crizotinib as a promising option. World J Clin Oncol 2025; 16(3): 103297 [DOI: 10.5306/wjco.v16.i3.103297]
Corresponding Author of This Article
Yan Zhou, MD, Assistant Professor, Department of Hepatobiliary Surgery, Zhuji People's Hospital, No. 9 Jianmin Road, Taozhu Street, Zhuji 311800, Zhejiang Province, China. 13606850272@163.com
Research Domain of This Article
Respiratory System
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Oncol. Mar 24, 2025; 16(3): 103297 Published online Mar 24, 2025. doi: 10.5306/wjco.v16.i3.103297
Therapeutic insights into epidermal growth factor receptor/reactive oxygen species proto-oncogene 1-receptor co-mutated non-small cell lung cancer: Crizotinib as a promising option
Yan Zhou, Bo-Tao Xu, Hai-Ying Zhou, Zhong-Tu Shang
Yan Zhou, Hai-Ying Zhou, Department of Hepatobiliary Surgery, Zhuji People's Hospital, Zhuji 311800, Zhejiang Province, China
Bo-Tao Xu, Department of Cardiothoracic Surgery, Zhuji People’s Hospital, Zhuji 311800, Zhejiang Province, China
Zhong-Tu Shang, Department of Respiratory Medicine, Zhuji People’s Hospital, Zhuji 311800, Zhejiang Province, China
Author contributions: Zhou Y was responsible for conceptualization, writing, reviewing and editing; Xu BT and Zhou HY were responsible for conceptualization and writing of the original draft; Shang ZT was responsible for formal analysis and validation; all authors participated in drafting the manuscript, have read and approved the final version of the manuscript.
Conflict-of-interest statement: Every author has stated that there is no commercial, professional, or personal conflict of interest relevant to the study, proving that it complies with the principles of publishing ethics.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Yan Zhou, MD, Assistant Professor, Department of Hepatobiliary Surgery, Zhuji People's Hospital, No. 9 Jianmin Road, Taozhu Street, Zhuji 311800, Zhejiang Province, China. 13606850272@163.com
Received: November 15, 2024 Revised: December 16, 2024 Accepted: December 25, 2024 Published online: March 24, 2025 Processing time: 68 Days and 4.4 Hours
Core Tip
Core Tip: Epidermal growth factor receptor (EGFR)/ reactive oxygen species proto-oncogene 1-receptor (ROS1) co-mutations in non-small cell lung cancer (NSCLC) are rare and present distinct therapeutic challenges. This case report demonstrates that ROS1 inhibition with crizotinib achieved superior disease control compared to EGFR-targeted therapy, underscoring the need for individualized treatment strategies that may benefit from biomarker guidance to identify the primary oncogenic driver. Tumor genetic heterogeneity could further affect therapeutic responses, highlighting the importance of advanced sequencing techniques in optimizing treatment plans. Larger studies are crucial to establish effective treatment protocols for NSCLC patients with EGFR/ROS1 co-mutations, with the potential to significantly improve survival outcomes in this complex patient population.
